The global osteoporosis drugs market is expected to reach USD
16.3 billion by 2025, according to a new study by Grand View Research, Inc. An
upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation
and increase in the prevalence of osteoporosis which is presumed to propel the
osteoporosis drugs market during the forecast period.
In addition, growing number of
patent expiries is fueling the high clinical urgency to use generic versions of
the established drugs, which is presumed to fuel generic osteoporosis drugs
market during the forecast period. The aforementioned factors cumulatively are
slated to present the with high potential growth opportunities over the coming
years.
Furthermore, rising number of
initiatives to increase the awareness levels pertaining to osteoporosis care
amongst the patients as well as the physicians is expected to widen the
osteoporosis market growth potential during the forecast period. For instance,
National Osteoporosis Foundation (NOF), a healthcare organization responsible
for National Bone Health Alliance and Fracture Liaison Service (FLS) care
coordination programs that focuses on elevating awareness levels as well as
provides training to healthcare professionals
Browse full research report on Osteoporosis Drugs Market:
http://www.grandviewresearch.com/industry-analysis/osteoporosis-drug-market
Further key findings from
the study suggest:
- Branded drugs held the dominant share of the product
segment in 2015. The dominant share can be attributed to extensive
utilization of bisphosphates, rank ligand inhibitors for the treatment of
osteoporosis, possessing high efficacy
- Generics are expected to witness at a lucrative CAGR
owing to consistent patent expiries over the coming years as well as high
clinical urgency for inexpensive medication in the emerging economies
- In 2015, North America accounted for the largest
share in the global osteoporosis drugs market owing to the presence of
established companies extensively involved in the commercialization of
branded therapeutics
- Asia Pacific is anticipated to grow at an exponential
CAGR as a consequence of favorable government initiatives promoting
information pertaining to osteoporosis care
- The key participants are employing sustainability
strategies promoting the adoption of osteoporosis therapeutics to gain
competitive advantage. For instance, Actavis Inc. announced to acquire
Warner Chilcott PLC in order to widen their product portfolio
Grand View Research has segmented the osteoporosis drugs
market on the basis of product and region:
Global Osteoporosis Product Outlook (Revenue, USD
Million, 2014 – 2025)
- Branded
- Bisphosphonates
- Parathyroid
Hormone Therapy
- Calcitonin
- Selective
Estrogen Inhibitors Modulator(SERM)
- Rank
Ligand Inhibitors
- Others
- Generics
Osteoporosis Drugs Regional Outlook (Revenue, USD
Billion, 2014 – 2025)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia
Pacific
- Japan
- China
- India
- Latin
America
- Mexico
- Brazil
- MEA
- South
Africa
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment